Upgrade to SI Premium - Free Trial

Ascendis Pharma (ASND)

251.93 -3.27 (1.28%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Form 6-K Ascendis Pharma A/S For: Jul 15 July 15, 2026 4:57 PM - SEC Filing Ascendis Pharma (ASND) PT Raised to $306 at BofA Securities July 14, 2026 6:03 AM - StreetInsider Ascendis Pharma (ASND) PT Raised to $280 at RBC Capital July 7, 2026 7:59 AM - StreetInsider Form 6-K Ascendis Pharma A/S For: Jun 30 June 30, 2026 4:06 PM - SEC Filing Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial June 30, 2026 8:30 AM - Globe NewsWire Form 6-K Ascendis Pharma A/S For: Jun 29 June 29, 2026 4:05 PM - SEC Filing Ascendis Pharma added to Russell 1000 and other indexes June 26, 2026 4:01 PM - StreetInsider Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap® June 26, 2026 4:01 PM - Globe NewsWire Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 June 25, 2026 4:01 PM - Globe NewsWire Form 6-K Ascendis Pharma A/S For: Jun 17 June 17, 2026 4:48 PM - SEC Filing Oppenheimer Reiterates Outperform Rating on Ascendis Pharma (ASND) June 15, 2026 7:07 AM - StreetInsider Form 6-K Ascendis Pharma A/S For: Jun 15 June 15, 2026 6:16 AM - SEC Filing Form 6-K Ascendis Pharma A/S For: Jun 12 June 12, 2026 6:04 AM - SEC Filing Ascendis reports 5-year TransCon PTH data in hypoparathyroidism patients June 11, 2026 4:01 PM - StreetInsider 5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism June 11, 2026 4:01 PM - Globe NewsWire Form 6-K Ascendis Pharma A/S For: Jun 10 June 10, 2026 4:09 PM - SEC Filing Oppenheimer Reiterates Outperform Rating on Ascendis Pharma (ASND) June 9, 2026 6:51 AM - StreetInsider Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 June 8, 2026 4:59 PM - Globe NewsWire Analysts see a buying opportunity in this pharma stock June 3, 2026 4:30 AM - StreetInsider Form 4 Ascendis Pharma A/S For: Jun 02 Filed by: SMITH SCOTT THOMAS June 2, 2026 4:25 PM - SEC Filing Form 4 Ascendis Pharma A/S For: May 29 Filed by: BIENAIME JEAN JACQUES June 1, 2026 4:11 PM - SEC Filing Form 4 Ascendis Pharma A/S For: May 29 Filed by: SMITH SCOTT THOMAS June 1, 2026 4:11 PM - SEC Filing Form 3/A Ascendis Pharma A/S For: Mar 18 Filed by: SMITH SCOTT THOMAS June 1, 2026 4:10 PM - SEC Filing JPMorgan says large-cap biotech is back as profits and pipelines fuel upside May 28, 2026 4:07 PM - StreetInsider Form 4 Ascendis Pharma A/S For: May 26 Filed by: BIENAIME JEAN JACQUES May 27, 2026 4:06 PM - SEC Filing Form SD Ascendis Pharma A/S May 22, 2026 4:03 PM - SEC Filing JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms May 20, 2026 3:10 PM - StreetInsider JPMorgan Reinstates Ascendis Pharma (ASND) at Overweight May 20, 2026 4:30 AM - StreetInsider Citi Starts Ascendis Pharma (ASND) at Buy May 18, 2026 4:14 PM - StreetInsider Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: JANUS HENDERSON GROUP PLC May 15, 2026 12:36 PM - SEC Filing Ascendis Pharma (ASND) PT Raised to $329 at Evercore ISI May 15, 2026 7:15 AM - StreetInsider Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: Capital International Investors May 14, 2026 12:53 PM - SEC Filing Form 6-K Ascendis Pharma A/S For: May 13 May 13, 2026 4:05 PM - SEC Filing Form 4 Ascendis Pharma A/S For: May 11 Filed by: JENSEN FLEMMING STEEN May 12, 2026 4:09 PM - SEC Filing Form 144 Ascendis Pharma A/S Filed by: JENSEN FLEMMING STEEN May 11, 2026 3:37 PM - SEC Filing Ascendis Pharma (ASND) PT Raised to $345 at Barclays May 11, 2026 3:26 AM - StreetInsider Ascendis Pharma (ASND) PT Lowered to $326 at Wells Fargo May 8, 2026 7:29 AM - StreetInsider Ascendis Pharma (ASND) PT Lowered to $328 at Stifel May 7, 2026 12:53 PM - StreetInsider Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: T. Rowe Price Investment Management, Inc. May 7, 2026 11:03 AM - SEC Filing Form SCHEDULE 13G Ascendis Pharma A/S Filed by: T. Rowe Price Investment Management, Inc. May 7, 2026 10:32 AM - SEC Filing Form 6-K Ascendis Pharma A/S For: May 07 May 7, 2026 7:50 AM - SEC Filing Form 6-K Ascendis Pharma A/S For: Mar 31 May 7, 2026 7:46 AM - SEC Filing Ascendis Pharma (ASND) Tops Q1 EPS by 9c May 7, 2026 7:40 AM - StreetInsider Ascendis Pharma Reports First Quarter 2026 Financial Results May 7, 2026 7:30 AM - Globe NewsWire Ascendis reports sustained growth in achondroplasia trial subgroup May 6, 2026 4:01 PM - StreetInsider New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years May 6, 2026 4:01 PM - Globe NewsWire Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: FMR LLC May 6, 2026 11:01 AM - SEC Filing Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026 April 30, 2026 4:01 PM - Globe NewsWire Full Article List